Cilomilast is a second-generation phosphodiesterase-4 (PDE4) inhibitor primarily developed to treat chronic obstructive pulmonary disease by reducing airway inflammation, bronchoconstriction, and mucus… Read more
Cilomilast is a second-generation phosphodiesterase-4 (PDE4) inhibitor primarily developed to treat chronic obstructive pulmonary disease by reducing airway inflammation, bronchoconstriction, and mucus hypersecretion. This category provides essential analytical tools for pharmaceutical research, including reference standards of the active pharmaceutical ingredient, as well as associated impurities and stable isotope labelled compounds such as Cilomilast-d9. These high-quality materials are critical for accurate impurity profiling, method development, and validation during the quality control process. By providing precise, reliable standards for testing, these compounds support regulatory compliance and ensure that the rigorous demands of pharmaceutical analysis are met throughout the drug development lifecycle. Laboratories rely on these specific reference materials to monitor degradation products and quantify metabolites, ensuring the overall safety and efficacy of therapeutic formulations during analytical testing and routine batch release.